Hydroxycobalamin & Rural Emergency Medical Services Cyanide Exposure

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The costs to a rural emergency medical services (EMS) system of a change from a traditional cyanide antidote kit to a kit containing hydroxocobalamin alone are currently unknown. The purpose of this study is to use current EMS data to calculate the costs to a rural EMS system associated with the adoption of a hydroxocobalamin protocol for the treatment of suspected cyanide exposure.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT05194358` - Study of SIAN Nasal Spray in Healthy Adults	Phase 1

NCT number	NCT01656616
Study type	Observational
Source	Maine Medical Center
Contact
Status	Withdrawn
Phase	N/A
Start date	August 1, 2012
Completion date	August 1, 2012

Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms